Bristol-Myers Squibb Company Q2 2026 Earnings Recap

Shares rose 3.5% following Q2 results that showed solid sales growth from the company’s growth portfolio and an upward revision to full-year revenue and adjusted EPS guidance, signaling investor approval of the company’s execution and pipeline progress.

Key Takeaways

• Growth portfolio sales increased 14%, driven by 10 products attaining double-digit growth, including Reblozyl, Breyanzi, Camzyos, Opdualag, and Qvantig.
• Full-year 2026 revenue and adjusted EPS guidance were raised, reflecting confidence in ongoing commercial momentum.
• Key late-stage pipeline highlights include positive Phase III data for MeziKd in multiple myeloma, encouraging results from ADC programs in solid tumors, and ongoing development of multiple pivotal-readout assets.
• Timing update on milvexian’s atrial fibrillation study pushed to Q1 2027 due to slower event accrual; Alzheimer’s psychosis program readouts expected in 2027 as well.
• The company is preparing for the August 17 PDUFA date for iberdomide, which may launch as the first CELMoD commercial product.